Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
Rybak JM, Marx K, Martin CA.
Pharmacotherapy · review; journal article · DOI 10.1002/phar.1491 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för tedizolid. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
20 träffarPlatelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.
Lodise TP, Fang E, Minassian SL, Prokocimer PG.
Antimicrob Agents Chemother · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1128/aac.03509-14Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.
Zurenko G, Bien P, Bensaci M, Patel HN, Thorne G.
Ann Clin Microbiol Antimicrob · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12941-014-0046-0Pharmaceutical approval update.
Goldenberg MM.
P T · other; journal articlePharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
Flanagan S, Minassian SL, Morris D, Ponnuraj R, Marbury TC, Alcorn HW, Fang E, Prokocimer P.
Antimicrob Agents Chemother · clinical trial; research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.03431-14Tedizolid population pharmacokinetics, exposure response, and target attainment.
Flanagan S, Passarell J, Lu Q, Fiedler-Kelly J, Ludwig E, Prokocimer P.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.03423-14Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections.
Wong E, Rab S.
P T · other; journal articleSingle- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.
Flanagan S, Fang E, Muñoz KA, Minassian SL, Prokocimer PG.
Pharmacotherapy · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1002/phar.1458Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P.
Lancet Infect Dis · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1473-3099(14)70737-6Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.
Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, Prokocimer P.
Drug Metab Dispos · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1124/dmd.113.056697Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages.
Molina-Torres CA, Barba-Marines A, Valles-Guerra O, Ocampo-Candiani J, Cavazos-Rocha N, Pucci MJ, Castro-Garza J, Vera-Cabrera L.
Ann Clin Microbiol Antimicrob · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1186/1476-0711-13-13Tedizolid: a new oxazolidinone antimicrobial.
Kisgen JJ, Mansour H, Unger NR, Childs LM.
Am J Health Syst Pharm · comparative study; review; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.2146/ajhp130482Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.
Rodvold KA, McConeghy KW.
Clin Infect Dis · historical article; research support, non-u.s. gov't; review; journal article · DOI 10.1093/cid/cit614Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.
Lodise TP, Drusano GL.
Clin Infect Dis · research support, non-u.s. gov't; review; journal article · DOI 10.1093/cid/cit615Tedizolid for the management of human infections: in vitro characteristics.
Locke JB, Zurenko GE, Shaw KJ, Bartizal K.
Clin Infect Dis · research support, non-u.s. gov't; review; journal article · DOI 10.1093/cid/cit616Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.
O'Riordan W, Green S, Mehra P, De Anda C, Fang E, Prokocimer P.
Clin Infect Dis · research support, non-u.s. gov't; review; journal article · DOI 10.1093/cid/cit617Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary.
Das D, Tulkens PM, Mehra P, Fang E, Prokocimer P.
Clin Infect Dis · research support, non-u.s. gov't; review; journal article · DOI 10.1093/cid/cit618Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug.
Flanagan SD, Bien PA, Muñoz KA, Minassian SL, Prokocimer PG.
Pharmacotherapy · comparative study; research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/phar.1337Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins.
Thomson KS, Goering RV.
Antimicrob Agents Chemother · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1128/aac.00274-13Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.
Urbina O, Ferrández O, Espona M, Salas E, Ferrández I, Grau S.
Drug Des Devel Ther · comparative study; review-article; review; journal article · DOI 10.2147/dddt.s30728